Genentech cease rDNA commercialisation
Genentech and Alkermes have decided to discontinue commercialisation of Nutropin Depot(somatropin (rDNA origin) for injectable suspension) for commercial reasons
Genentech and Alkermes have decided to discontinue commercialisation of Nutropin Depot(somatropin (rDNA origin) for injectable suspension) for commercial reasons
The decision is based on the significant resources required by both companies to continue manufacturing and commercialising the product.
Nutropin Depot, approved in 1999 by the FDA as a treatment for growth hormone deficiency in pediatric patients, is a long-acting form of Genentech's human growth hormone using Alkermes' ProLease injectable extended-release drug delivery system. Alkermes performs the manufacturing operations that convert Genentech's bulk product somatropin (somatropin (rDNA origin) for injectable suspension) into the long-acting dosage form. Genentech markets the product as Nutropin Depot in the United States.
'We are committed to patients who require growth hormone therapy and will continue to provide options with our current Nutropin line,' commented Dr Susan Hellmann,MPH, president, product development at Genentech.'Our goal is to work to ensure that patients' therapies are not disrupted during the transition.'